Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the study alliance leukemia

被引：41

作者：

Mueller-Tidow, C. ^{[1
,2
]}

Tschanter, P. ^{[1
,2
]}

Roellig, C. ^{[3
]}

Thiede, C. ^{[3
]}

Koschmieder, A. ^{[2
,4
]}

Stelljes, M. ^{[2
]}

Koschmieder, S. ^{[2
,4
]}

Dugas, M. ^{[5
]}

Gerss, J. ^{[6
]}

Butterfass-Bahloul, T. ^{[7
]}

Wagner, R. ^{[7
]}

Eveslage, M. ^{[6
]}

Thiem, U. ^{[8
]}

Krause, S. W. ^{[9
]}

Kaiser, U. ^{[10
]}

Kunzmann, V. ^{[11
]}

Steffen, B. ^{[12
]}

Noppeney, R. ^{[13
]}

Herr, W. ^{[14
]}

Baldus, C. D. ^{[15
]}

Schmitz, N. ^{[16
]}

Goetze, K. ^{[17
]}

Reichle, A. ^{[14
]}

Kaufmann, M. ^{[18
]}

Neubauer, A. ^{[19
]}

Schaefer-Eckart, K. ^{[20
]}

Haenel, M. ^{[21
]}

Peceny, R. ^{[22
]}

Frickhofen, N. ^{[23
]}

Kiehl, M. ^{[24
]}

Giagounidis, A. ^{[25
]}

Goerner, M. ^{[26
]}

Repp, R. ^{[27
]}

Link, H. ^{[28
]}

Kiani, A. ^{[29
]}

Naumann, R. ^{[30
]}

Bruemmendorf, Th ^{[4
]}

Serve, H. ^{[12
]}

Ehninger, G. ^{[3
]}

Berdel, W. E. ^{[2
]}

Krug, U. ^{[2
,31
]}

机构：

[1] Univ Halle, Dept Med Hematol & Oncol, Ernst Grube Str 40, D-06120 Halle, Germany

[2] Univ Munster, Dept Med Hematol Oncol & Pneumol A, Munster, Germany

[3] Dresden Univ, Med Ctr, Dept Internal Med 1, Dresden, Germany

[4] RWTH Aachen Univ Hosp, Dept Hematol Oncol Hemostaseol & Stem Cell Transp, Aachen, Germany

[5] Univ Hosp Muenster, Inst Med Informat, Munster, Germany

[6] Univ Hosp Muenster, Inst Biometry, Munster, Germany

[7] Univ Hosp Muenster, Ctr Clin Trials, Munster, Germany

[8] Univ Bochum, Dept Med Informat Biometry & Epidemiol, Bochum, Germany

[9] Univ Erlangen Nurnberg, Med Ctr, Dept Internal Med 5, D-91054 Erlangen, Germany

[10] St Bernward Hosp, Hematol & Oncol, Hildesheim, Germany

[11] Univ Wurzburg, Dept Internal Med 2, D-97070 Wurzburg, Germany

[12] Goethe Univ Frankfurt, Dept Med Hematol Oncol, D-60054 Frankfurt, Germany

[13] Univ Essen Gesamthsch, Med Ctr, Dept Hematol, Essen, Germany

[14] Univ Regensburg, Dept Hematol Oncol, D-93053 Regensburg, Germany

[15] Charite Campus Benjamin Franklin, Dept Hematol & Oncol, Berlin, Germany

[16] ASKLEPIOS Klin St Georg, Dept Hematol & Stem Cell Transplantat, Hamburg, Germany

[17] Univ Hosp Munich, Dept Internal Med 3, Munich, Germany

[18] Robert Bosch Krankenhaus, Hematol & Oncol, Stuttgart, Germany

[19] Univ Marburg, Dept Hematol Oncol & Immunol, Marburg, Germany

[20] Klinikum Nuernberg Nord, Dept Internal Med 5, Nurnberg, Germany

[21] Klinikum Chemnitz GmbH, Dept Internal Med 3, Chemnitz, Germany

[22] Klinikum Osnabruck, Dept Hematol & Oncol, Osnabruck, Germany

[23] Dr Horst Schmidt Klin, Dept Hematol & Oncol, HSK, Wiesbaden, Germany

[24] Frankfurt Oder Gen Hosp, Dept Internal Med, Frankfurt, Germany

[25] Marien Hosp, Dept Hematol & Oncol, Dusseldorf, Germany

[26] Stadt Kliniken, Dept Hematol & Oncol, Bielefeld, Germany

[27] Klinikum Bruderwald, Dept Med 5, Bamberg, Germany

[28] Westpfalz Klinikum, Dept Internal Med 1, Kaiserslautern, Germany

[29] Klinikum Bayreuth, Dept Hematol & Onkol 4, Bayreuth, Germany

[30] Stiftungsklinikum Mittelrhein, Dept Internal Med, Koblenz, Germany

[31] Klinikum Leverkusen, Dept Med Hematol & Oncol, Leverkusen, Germany

来源：

LEUKEMIA | 2016年 / 30卷 / 03期

关键词：

CONVENTIONAL CARE REGIMENS; ELDERLY-PATIENTS; DNMT3A MUTATIONS; DNA METHYLATION; OPEN-LABEL; PHASE-III; 5-AZACYTIDINE; OUTCOMES; RECOMMENDATIONS; DECITABINE;

D O I：

10.1038/leu.2015.306

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

DNA methylation changes are a constant feature of acute myeloid leukemia. Hypomethylating drugs such as azacitidine are active in acute myeloid leukemia (AML) as monotherapy. Azacitidine monotherapy is not curative. The AML-AZA trial tested the hypothesis that DNA methyltransferase inhibitors such as azacitidine can improve chemotherapy outcome in AML. This randomized, controlled trial compared the efficacy of azacitidine applied before each cycle of intensive chemotherapy with chemotherapy alone in older patients with untreated AML. Event-free survival (EFS) was the primary end point. In total, 214 patients with a median age of 70 years were randomized to azacitidine/chemotherapy (arm-A) or chemotherapy (arm-B). More arm-A patients (39/105; 37%) than arm-B (25/109; 23%) showed adverse cytogenetics (P = 0.057). Adverse events were more frequent in arm-A (15.44) versus 13.52 in arm-B, (P = 0.26), but early death rates did not differ significantly (30-day mortality: 6% versus 5%, P = 0.76). Median EFS was 6 months in both arms (P = 0.96). Median overall survival was 15 months for patients in arm-A compared with 21 months in arm-B (P = 0.35) Azacitidine added to standard chemotherapy increases toxicity in older patients with AML, but provides no additional benefit for unselected patients.

引用

页码：555 / 561

页数：7

共 50 条

[1] Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the study alliance leukemia
C Müller-Tidow
P Tschanter
C Röllig
C Thiede
A Koschmieder
M Stelljes
S Koschmieder
M Dugas
J Gerss
T Butterfaß-Bahloul
R Wagner
M Eveslage
U Thiem
S W Krause
U Kaiser
V Kunzmann
B Steffen
R Noppeney
W Herr
C D Baldus
N Schmitz
K Götze
A Reichle
M Kaufmann
A Neubauer
K Schäfer-Eckart
M Hänel
R Peceny
N Frickhofen
M Kiehl
A Giagounidis
M Görner
R Repp
H Link
A Kiani
R Naumann
T H Brümmendorf
H Serve
G Ehninger
W E Berdel
U Krug
Leukemia, 2016, 30 : 555 - 561
[2] Azacitidine Followed By Intensive Induction/Consolidation Chemotherapy in Older Patients with Acute Myeloid Leukemia (AML): Results from the Randomized AML-AZA Trial of the Study Alliance Leukemias (SAL)
Mueller-Tidow, Carsten
Tschanter, Petra
Krug, Utz
Goellner, Stefanie
Roellig, Christoph
Thiede, Christian
Koschmieder, Anja
Dugas, Martin
Gerss, Joachim
Butterfass-Bahloul, Trude
Wagner, Ruth
Krause, Stefan W.
Kaiser, Ulrich
Kunzmann, Volker
Steffen, Bjoern
Noppeney, Richard
Herr, Wolfgang
Baldus, Claudia D.
Schmitz, Norbert
Goetze, Katharina
Reichle, Albrecht
Kaufmann, Martin
Neubauer, Andreas
Schaefer-Eckart, Kerstin
Haenel, Mathias
Peceny, Rudolf
Bea, Haack
Meredith, Lilly
Frickhofen, Norbert
Kiehl, Michael G.
Giagounidis, Aristoteles A. N.
Goerner, Martin
Repp, Roland
Naumann, Ralph
Link, Hartmut
Kiani, Alexander
Koschmieder, Steffen
Bruemmendorf, Tim H.
Serve, Hubert
Ehninger, Gerhard
Berdel, Wolfgang E.
BLOOD, 2014, 124 (21)
[3] Addition of 5-Azacitidine to Standard Induction Therapy Is Feasible In Older Patients with Acute Myeloid Leukemia: The AML-AZA Trial of the SAL Study Group.
Krug, Utz O.
Koschmieder, Anja
Gerss, Joachim
Serve, Hubert
Steffen, Bjoern
Bug, Gesine
Schaich, Markus
Brandts, Christian
Roellig, Christoph
Ehninger, Gerhard
Duehrsen, Ulrich
Noppeney, Richard
Berdel, Wolfgang E.
Koschmieder, Steffen
Mueller-Tidow, Carsten
BLOOD, 2010, 116 (21) : 900 - 900
[4] OVERALL SURVIVAL (OS) AND CLINICAL OUTCOMES IN OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) TREATED WITH AZACITIDINE (AZA) OR INTENSIVE CHEMOTHERAPY (IC) IN THE AZA-AML-001 STUDY
Doehner, H.
Selleslag, D.
Cavenagh, J.
Seymour, J. F.
Minden, M.
Recher, C.
Martinelli, G.
Mayer, J.
Font Lopez, P.
Kim, H. -J.
Chou, W. -C.
Kew, A.
Min, Y. H.
Songer, S.
Lucy, L. M.
Beach, C.
Dombret, H.
HAEMATOLOGICA, 2015, 100 : 215 - 216
[5] Siremadlin in Combination with Venetoclax (VEN) Plus Azacitidine (AZA) in Adult Patients with Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy: A Phase Ib/II Trial
Daver, Naval
Wei, Andrew H.
Stein, Eytan
DeAngelo, Daniel J.
Pathak, Dhrubajyoti
Xu, Yunnan
Grzesiak, Stephanie
Venditti, Adriano
BLOOD, 2022, 140 : 11625 - 11627
[6] Combination therapy involving azacitidine for acute myeloid leukemia patients ineligible for intensive chemotherapy
Li, Juan
Fu, Shuying
Ye, Chunmei
Li, Jun
LEUKEMIA RESEARCH, 2025, 148
[7] OVERALL SURVIVAL (SG) AND CLINICAL RESULTS IN OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA (LMA) TREATED WITH AZACITIDINE (AZA) OR WITH INTENSIVE CHEMOTHERAPY (QI) IN AZA-AML-001
Font Lopez, P.
Dombret, H.
Selleslag, D.
Songer, S.
Lucy Lela, M.
Beach, C. L.
Doeher, H.
HAEMATOLOGICA, 2015, 100 : 22 - 23
[8] Decision criteria for the futility of intensive chemotherapy in older patients with acute myeloid leukemia (AML)
Dombrel, Herve
Malfuson, Jean-Valere
Etienne, Anne
Turlure, Pascal
de Revel, Thierry
Thomas, Xavier
Contentin, Nathalie
Terre, Christine
Michallet, Mauricette
Castaigne, Sylvie
Bordessoule, Dominique
Vey, Norbert
Gardin, Claude
BLOOD, 2007, 110 (11) : 841A - 842A
[9] Azacitidine or intensive chemotherapy for older patients with secondary or therapy-related acute myeloid leukemia
Dumas, Pierre-Yves
Bertoli, Sarah
Berard, Emilie
Mediavilla, Clemence
Yon, Edwige
Tavitian, Suzanne
Leguay, Thibaut
Huguet, Francoise
Forcade, Edouard
Milpied, Noel
Sarry, Audrey
Sauvezie, Mathieu
Bories, Pierre
Pigneux, Arnaud
Recher, Christian
ONCOTARGET, 2017, 8 (45) : 79126 - 79136
[10] AML THERAPY: IS AZACYTIDINE AN ALTERNATIVE TO INTENSIVE CHEMOTHERAPY IN OLDER ACUTE MYELOID LEUKEMIA? A RETROSPECTIVE STUDY ON 334 OLDER AML PATIENTS
Bories, Pierre
ANNALS OF HEMATOLOGY, 2013, 92 : S4 - S4

← 1 2 3 4 5 →